Charles River Laboratories International (NYSE:CRL) Director Sells 24,042 Shares of Stock

Key Points

• Director James Foster sold 24,042 CRL shares at an average of $350, generating $8.41 million; the Rule 10b5-1 transaction reduced his holdings by 43.21% to 31,596 shares.
• Charles River Laboratories’ stock rose 3.3% to $356.76, near its 52-week high, despite the company reporting a 2.7% year-over-year revenue decline in its latest quarter.
• Analysts maintain a consensus “Moderate Buy” rating with an average price target of $302.33, while institutional investors own 98.91% of the company.

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) Director James Foster sold 24,042 shares of Charles River Laboratories International stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $350.00, for a total transaction of $8,414,700.00. Following the sale, the director owned 31,596 shares of the company's stock, valued at approximately $11,058,600. This trade represents a 43.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Trading Up 3.3%

Charles River Laboratories International stock traded up $11.39 during midday trading on Monday, reaching $356.76. The stock had a trading volume of 1,172,834 shares, compared to its average volume of 947,519. The stock has a market capitalization of $17.03 billion, a PE ratio of -73.56, a price-to-earnings-growth ratio of 3.23 and a beta of 1.40. Charles River Laboratories International, Inc. has a twelve month low of $146.20 and a twelve month high of $357.77. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The stock's 50-day simple moving average is $294.35 and its 200 day simple moving average is $233.67.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business's quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Analysts expect that Charles River Laboratories International, Inc. will post 11.38 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on CRL. CLSA lowered shares of Charles River Laboratories International from an "outperform" rating to a "hold" rating and set a $219.00 target price for the company. in a research note on Monday, July 20th. Royal Bank Of Canada raised their price target on shares of Charles River Laboratories International from $282.00 to $322.00 and gave the company an "outperform" rating in a research note on Friday, September 25th. Piper Sandler set a $300.00 price target on Charles River Laboratories International in a report on Monday, August 10th. JPMorgan Chase & Co. upgraded Charles River Laboratories International from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $180.00 to $310.00 in a research report on Thursday, August 6th. Finally, BNP Paribas Exane set a $250.00 price objective on Charles River Laboratories International in a research report on Wednesday, July 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $302.33.

Hedge Funds Weigh In On Charles River Laboratories International

Large investors have recently bought and sold shares of the stock. Amundi raised its position in Charles River Laboratories International by 175.2% during the first quarter. Amundi now owns 773,315 shares of the medical research company's stock valued at $133,397,000 after acquiring an additional 492,301 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Charles River Laboratories International by 14.6% in the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company's stock worth $285,001,000 after acquiring an additional 210,260 shares in the last quarter. Assenagon Asset Management S.A. grew its position in Charles River Laboratories International by 230.9% in the third quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company's stock worth $59,044,000 after acquiring an additional 142,716 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Charles River Laboratories International by 2,268.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 111,781 shares of the medical research company's stock worth $32,977,000 after purchasing an additional 107,061 shares during the last quarter. Finally, Ranger Investment Management L.P. acquired a new position in shares of Charles River Laboratories International during the 1st quarter worth $12,198,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.